Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

16-05-2023 | Metastasis | Original Article

Melanin-targeted [¹⁸F]-PFPN PET imaging for prognosticating patients with melanoma

Authors: Xiao Zhang, Zhaoguo Lin, Mengting Li, Yongkang Gai, Huaiyuan Zheng, Li Fan, Weiwei Ruan, Fan Hu, Jing Chen, Xiaoli Lan

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 10/2023

Abstract

Purpose

Positron emission tomography (PET) using [¹⁸F]-PFPN, a melanin-targeted imaging tracer, has excellent diagnostic performance in patients with melanoma. This study aimed to investigate its value in prognostication and determine predictors of progression-free survival (PFS) and overall survival (OS).

Methods

We reviewed melanoma patients who underwent [¹⁸F]-PFPN and [¹⁸F]-FDG PET from February 2021 to July 2022. Clinical characteristics, follow-up data, and the following [¹⁸F]-PFPN PET parameters were recorded: maximum standardized uptake value (SUV_max), whole-body melanotic tumoral volume (WBMTV), and whole-body total lesion melanin (WBTLM). Receiver operating characteristic (ROC), Kaplan–Meier and Cox regression analyses were performed.

Results

Seventy-six patients (47 men and 29 women; mean age, 57.99 ± 10.72 years) were included for analysis. Median follow-up was 12.0 months (range: 1–22 months). Eighteen patients died and 38 experienced progression. Median OS was 17.60 months (95% confidence interval, 15.89–19.31). In the ROC analysis, [¹⁸F]-PFPN PET parameters were superior to those of [¹⁸F]-FDG PET in prognosticating death and disease progression. PFS and OS were significantly better in patients with lower SUV_max, WBMTV, and WBTLM on [¹⁸F]-PFPN PET (log-rank, P < 0.05). In the univariate analyses, distant metastasis, SUV_max, WBMTV, and WBTLM were significantly associated with cumulative incidence of PFS and OS (P < 0.05). In the multivariate analysis, SUV_max was an independent predictor of PFS and OS.

Conclusions

[¹⁸F]-PFPN PET has a role in prognostication of melanoma patients. Patients with higher [¹⁸F]-PFPN SUV_max have worse prognosis.

Clinical Trial Registration

ClinicalTrials.gov, NCT05645484. Registered 9 December, 2022, https://clinicaltrials.gov/ct2/show/NCT05645484?cond=The+Prognostic+Value+of+18F-PFPN+PET+Imaging+in+Patients+With+Malignant+Melanoma&draw=2&rank=1

Available only for authorised users

Shain AH, Bastian BC. From melanocytes to melanomas. Nat Rev Cancer. 2016;16:345–58. https://doi.org/10.1038/nrc.2016.37.CrossRefPubMed

Arnold M, Singh D, Laversanne M, Vignat J, Vaccarella S, Meheus F, et al. Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040. JAMA Dermatol. 2022;158:495–503. https://doi.org/10.1001/jamadermatol.2022.0160.CrossRefPubMedPubMedCentral

Luke JJ, Flaherty KT, Ribas A, Long GV. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol. 2017;14:463–82. https://doi.org/10.1038/nrclinonc.2017.43.CrossRefPubMed

Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, et al. Melanoma staging Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67:472–92.CrossRefPubMedPubMedCentral

Strudel M, Festino L, Vanella V, Beretta M, Marincola FM, Ascierto PA. Melanoma: Prognostic Factors and Factors Predictive of Response to Therapy. Curr Med Chem. 2020;27:2792–813. https://doi.org/10.2174/0929867326666191205160007.CrossRefPubMed

Brochez L, Naeyaert JM. Serological markers for melanoma. Br J Dermatol. 2000;143:256–68. https://doi.org/10.1046/j.1365-2133.2000.03649.x.CrossRefPubMed

Prichard RS, Hill AD, Skehan SJ, O’Higgins NJ. Positron emission tomography for staging and management of malignant melanoma. Br J Surg. 2002;89:389–96. https://doi.org/10.1046/j.0007-1323.2002.02059.x.CrossRefPubMed

Annovazzi A, Ferraresi V, Rea S, Russillo M, Renna D, Carpano S, et al. Prognostic value of total metabolic tumour volume and therapy-response assessment by [(18)F]FDG PET/CT in patients with metastatic melanoma treated with BRAF/MEK inhibitors. Eur Radiol. 2022;32:3398–407. https://doi.org/10.1007/s00330-021-08355-1.CrossRefPubMed

Reinert CP, Gatidis S, Sekler J, Dittmann H, Pfannenberg C, la Fougere C, et al. Clinical and prognostic value of tumor volumetric parameters in melanoma patients undergoing (18)F-FDG-PET/CT: a comparison with serologic markers of tumor burden and inflammation. Cancer Imaging. 2020;20:44. https://doi.org/10.1186/s40644-020-00322-1.CrossRefPubMedPubMedCentral

10.

Seban RD, Nemer JS, Marabelle A, Yeh R, Deutsch E, Ammari S, et al. Prognostic and theranostic ¹⁸F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics. Eur J Nucl Med Mol Imaging. 2019;46:2298–310. https://doi.org/10.1007/s00259-019-04411-7.CrossRefPubMed

11.

Stas M, Stroobants S, Dupont P, Gysen M, Hoe LV, Garmyn M, et al. 18-FDG PET scan in the staging of recurrent melanoma: additional value and therapeutic impact. Melanoma Res. 2002;12:479–90. https://doi.org/10.1097/00008390-200209000-00010.CrossRefPubMed

12.

Kudura K, Dimitriou F, Mihic-Probst D, Muehlematter UJ, Kutzker T, Basler L, et al. Malignancy Rate of Indeterminate Findings on FDG-PET/CT in Cutaneous Melanoma Patients. Diagnostics. 2021;11:883. https://doi.org/10.3390/diagnostics11050883.CrossRefPubMedPubMedCentral

13.

Rouanet J, Quintana M, Auzeloux P, Cachin F, Degoul F. Benzamide derivative radiotracers targeting melanin for melanoma imaging and therapy: Preclinical/clinical development and combination with other treatments. Pharmacol Ther. 2021;224:107829. https://doi.org/10.1016/j.pharmthera.2021.107829.CrossRefPubMed

14.

Rizzo-Padoin N, Chaussard M, Vignal N, Kotula E, Tsoupko-Sitnikov V, Vaz S, et al. [(18)F]MEL050 as a melanin-targeted PET tracer: Fully automated radiosynthesis and comparison to (18)F-FDG for the detection of pigmented melanoma in mice primary subcutaneous tumors and pulmonary metastases. Nucl Med Biol. 2016;43:773–80. https://doi.org/10.1016/j.nucmedbio.2016.08.010.CrossRefPubMed

15.

Liu X, Pham TQ, Berghofer P, Chapman J, Greguric I, Mitchell P, et al. Synthesis and evaluation of novel radioiodinated nicotinamides for malignant melanoma. Nucl Med Biol. 2008;35:769–81. https://doi.org/10.1016/j.nucmedbio.2008.05.011.CrossRefPubMed

16.

Zhang X, Li M, Gai Y, Chen J, Tao J, Yang L, et al. (18)F-PFPN PET: a new and attractive imaging modality for patients with malignant melanoma. J Nucl Med. 2022. https://doi.org/10.2967/jnumed.121.263179.CrossRefPubMedPubMedCentral

17.

Ma X, Wang S, Wang S, Liu D, Zhao X, Chen H, et al. Biodistribution, Radiation Dosimetry, and Clinical Application of a Melanin-Targeted PET Probe, ¹⁸F–P3BZA, in Patients. J Nucl Med. 2019;60:16–22. https://doi.org/10.2967/jnumed.118.209643.CrossRefPubMed

18.

Xu X, Yuan L, Yin L, Jiang Y, Gai Y, Liu Q, et al. Synthesis and Preclinical Evaluation of ¹⁸F-PEG₃-FPN for the Detection of Metastatic Pigmented Melanoma. Mol Pharm. 2017;14:3896–905. https://doi.org/10.1021/acs.molpharmaceut.7b00607.CrossRefPubMed

19.

Qin C, Shao F, Hu F, Song W, Song Y, Guo J, et al. ¹⁸F-FDG PET/CT in diagnostic and prognostic evaluation of patients with cardiac masses: a retrospective study. Eur J Nucl Med Mol Imaging. 2020;47:1083–93. https://doi.org/10.1007/s00259-019-04632-w.CrossRefPubMed

20.

Jimbow K, Lee SK, King MG, Hara H, Chen H, Dakour J, et al. Melanin pigments and melanosomal proteins as differentiation markers unique to normal and neoplastic melanocytes. J Invest Dermatol. 1993;100:259s-s268. https://doi.org/10.1111/1523-1747.ep12470103.CrossRefPubMed

21.

Slominski RM, Sarna T, Plonka PM, Raman C, Brozyna AA, Slominski AT. Melanoma, Melanin, and Melanogenesis: The Yin and Yang Relationship. Front Oncol. 2022;12:842496. https://doi.org/10.3389/fonc.2022.842496.CrossRefPubMedPubMedCentral

22.

Brozyna AA, Jozwicki W, Carlson JA, Slominski AT. Melanogenesis affects overall and disease-free survival in patients with stage III and IV melanoma. Hum Pathol. 2013;44:2071–4. https://doi.org/10.1016/j.humpath.2013.02.022.CrossRefPubMedPubMedCentral

23.

Kabbarah O, Chin L. Revealing the genomic heterogeneity of melanoma. Cancer Cell. 2005;8:439–41. https://doi.org/10.1016/j.ccr.2005.11.008.CrossRefPubMed

24.

Teh YL, Goh WL, Tan SH, Yong G, Sairi ANH, Soo KC, et al. Treatment and outcomes of melanoma in Asia: Results from the National Cancer Centre Singapore. Asia Pac J Clin Oncol. 2018;14:e95–102. https://doi.org/10.1111/ajco.12802.CrossRefPubMed

25.

Spagnolo F, Caltabiano G, Queirolo P. Uveal melanoma. Cancer Treat Rev. 2012;38:549–53. https://doi.org/10.1016/j.ctrv.2012.01.002.CrossRefPubMed

26.

Sanli Y, Leake J, Odu A, Xi Y, Subramaniam RM. Tumor heterogeneity on FDG PET/CT and immunotherapy: An imaging biomarker for predicting treatment response in patients with metastatic melanoma. AJR Am J Roentgenol. 2019;212:1318–26. https://doi.org/10.2214/ajr.18.19796.

27.

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71:7–33. https://doi.org/10.3322/caac.21654.CrossRefPubMed

28.

Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Coit DG, Atkins MB, et al. Age as a prognostic factor in patients with localized melanoma and regional metastases. Ann Surg Oncol. 2013;20:3961–8. https://doi.org/10.1245/s10434-013-3100-9.CrossRefPubMedPubMedCentral

29.

Rees MJ, Liao H, Spillane J, Speakman D, McCormack C, Donahoe S, et al. Localized melanoma in older patients, the impact of increasing age and comorbid medical conditions. Eur J Surg Oncol. 2016;42:1359–66. https://doi.org/10.1016/j.ejso.2016.01.010.CrossRefPubMed

30.

Rogiers A, van den Oord JJ, Garmyn M, Stas M, Kenis C, Wildiers H, et al. Novel therapies for metastatic melanoma: An update on their use in older patients. Drugs Aging. 2015;32:821–34. https://doi.org/10.1007/s40266-015-0304-7.CrossRefPubMed

31.

Ciocan D, Barbe C, Aubin F, Granel-Brocard F, Lipsker D, Velten M, et al. Distinctive features of melanoma and its management in elderly patients: a population-based study in France. JAMA Dermatol. 2013;149:1150–7. https://doi.org/10.1001/jamadermatol.2013.706.CrossRefPubMed

32.

Larkin J, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, et al. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol. 2014;15:436–44. https://doi.org/10.1016/s1470-2045(14)70051-8.CrossRefPubMed

Title: Melanin-targeted [18F]-PFPN PET imaging for prognosticating patients with melanoma
Authors: Xiao Zhang
Zhaoguo Lin
Mengting Li
Yongkang Gai
Huaiyuan Zheng
Li Fan
Weiwei Ruan
Fan Hu
Jing Chen
Xiaoli Lan
Publication date: 16-05-2023
Publisher: Springer Berlin Heidelberg
Keywords: Metastasis
Melanoma
Melanoma
Positron Emission Tomography
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 10/2023
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-023-06258-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Melanin-targeted [¹⁸F]-PFPN PET imaging for prognosticating patients with melanoma

Abstract

Purpose

Methods

Results

Conclusions

Clinical Trial Registration

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Clinical Trial Registration

Please log in to get access to this content

Other articles of this Issue 10/2023

Fibroblast activation protein (FAP)-targeted radionuclide therapy: which ligand is the best?

Relationship between SUVmax on 18F-FDG PET and PD-L1 expression in hepatocellular carcinoma

Machine learning identifies multi-parametric functional PET/MR imaging cluster to predict radiation resistance in preclinical head and neck cancer models

PET imaging of tumor vascular normalization in hepatocellular carcinoma

Sarcoidosis mimicking nodal manifestations of marginal zone lymphoma

Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides